Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC

被引：0
|
作者：
de Azevedo, Ricardo A.
Turner, Broderick
Jayaprakash, Priyamvada
Bhanu, Krithikaa Rajkumar
Srinivasamani, Anupallavi
Morrow, Brittany
Winkler, Michelle
Hedge, Shweta Mahendra
Liu, Arthur
Slay, Ravaen
Curran, Michael A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5745
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy
    Ohkuma, Ryotaro
    Fujimoto, Yuki
    Ieguchi, Katsuaki
    Onishi, Nobuyuki
    Watanabe, Makoto
    Takayanagi, Daisuke
    Goshima, Tsubasa
    Horiike, Atsushi
    Hamada, Kazuyuki
    Ariizumi, Hirotsugu
    Hirasawa, Yuya
    Ishiguro, Tomoyuki
    Suzuki, Risako
    Iriguchi, Nana
    Tsurui, Toshiaki
    Sasaki, Yosuke
    Homma, Mayumi
    Yamochi, Toshiko
    Yoshimura, Kiyoshi
    Tsuji, Mayumi
    Kiuchi, Yuji
    Kobayashi, Shinichi
    Tsunoda, Takuya
    Wada, Satoshi
    [J]. ONCOLOGY LETTERS, 2023, 26 (03)
  • [22] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Park, J. J.
    Parakh, S.
    Mendis, S.
    Rai, R.
    Lo, S.
    Haydon, A.
    Andrews, M. C.
    Cebon, J.
    Guminski, A.
    Kefford, R.
    Long, G. V.
    Menzies, A. M.
    Klein, O.
    Carlino, M. S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [23] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Sagun Parakh
    John J Park
    Shehara Mendis
    Rajat Rai
    Wen Xu
    Serigne Lo
    Martin Drummond
    Catherine Rowe
    Annie Wong
    Grant McArthur
    Andrew Haydon
    Miles C Andrews
    Jonathan Cebon
    Alex Guminski
    Richard F Kefford
    Georgina V Long
    Alexander M Menzies
    Oliver Klein
    Matteo S Carlino
    [J]. British Journal of Cancer, 2017, 116 : 1558 - 1563
  • [24] Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
    Wang, Lei
    Feng, Jin-Kai
    Lu, Chong-De
    Wu, Jia-Yi
    Zhou, Bin
    Wang, Kang
    Wei, Xu-Biao
    Liang, Chao
    Zhou, Hong-Kun
    Shi, Jie
    Guo, Wei-Xing
    Lau, Wan Yee
    Yan, Mao-Lin
    Cheng, Shu-Qun
    [J]. ONCOLOGIST, 2024, 29 (08): : e1041 - e1050
  • [25] Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).
    Sun, Hui-Chuan
    Huang, Cheng
    Zhu, Xiao-Dong
    Shen, Ying-Hao
    Wu, Dong
    Ji, Yuan
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy
    Nikoo, Marzieh
    Hassan, Zahraa F.
    Mardasi, Mahsa
    Rostamnezhad, Elmira
    Roozbahani, Fatemeh
    Rahimi, Sahel
    Mohammadi, Javad
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2023, 247
  • [27] Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies
    Barcena-Varela, Marina
    [J]. JOURNAL OF HEPATOLOGY, 2022, 77 (01) : 9 - 11
  • [28] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [30] Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
    Lv, Tingting
    Xiong, Xiaofeng
    Yan, Wei
    Liu, Mei
    Xu, Hongwei
    He, Qin
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
12345